Mobia Medical, Inc. (MOBI)
| Market Cap | 305.61M |
| Revenue (ttm) | 45.28M +104.8% |
| Net Income | -64.14M |
| EPS | -9.35 |
| Shares Out | 33.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 280,011 |
| Open | 9.02 |
| Previous Close | 9.03 |
| Day's Range | 8.76 - 9.32 |
| 52-Week Range | 8.45 - 15.29 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 17.75 (+93.36%) |
| Est. Earnings | Nov 12, 2026 |
About MOBI
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MOBI stock is "Strong Buy." The 12-month stock price target is $17.75, which is an increase of 93.36% from the latest price.
News
Mobia Medical announces addition of paired VNS to updated AHA stroke guidelines
Mobia Medical (MOBI) announced that implantable paired Vagus Nerve Stimulation, or VNS, has been recognized in the 2026 Guideline for Adult Stroke Rehabilitation and Recovery: A Guideline From the Ame...
Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines
AUSTIN, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, toda...
Mobia Medical price target raised to $17 from $15 at JPMorgan
JPMorgan analyst Robbie Marcus raised the firm’s price target on Mobia Medical (MOBI) to $17 from $15 and keeps an Overweight rating on the shares.
Mobia Medical Slides: Investor presentation
Mobia Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Mobia Medical Earnings Call Transcript: Q2 2026
Q2 2026 revenue doubled year-over-year to $13.5M, driven by strong Vivistim adoption and territory expansion. IPO proceeds are fueling commercial growth, with full-year revenue guidance set at $54–$56M, reflecting 69–75% growth. Gross margin remains robust at 83.2%.
Mobia Medical Earnings release: Q2 2026
Mobia Medical released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Mobia Medical Quarterly report: Q2 2026
Mobia Medical has published its Q2 2026 quarterly earnings report on August 11, 2026.
Mobia Medical Reports Second Quarter 2026 Financial Results
AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, toda...
Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
AUSTIN, Texas, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor...
Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor ...
Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors
AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor ...
Mobia Medical publishes two-year follow-up data from VNS-REHAB study
Mobia Medical (MOBI) announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the official peer-reviewed journal of the American Academy of Neurology. The findings d...
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years Findings published in Neurology® ...
Mobia Medical Announces Vivistim® Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule
AUSTIN, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor ...
Mobia Medical Inc trading resumes
09:38 EDT Mobia Medical (MOBI) Inc trading resumes
Mobia Medical Inc trading halted, volatility trading pause
09:33 EDT Mobia Medical (MOBI) Inc trading halted, volatility trading pause
Mobia Medical Quarterly report: Q1 2026
Mobia Medical has published its Q1 2026 quarterly earnings report on June 4, 2026.
Mobia Medical Slides: Corporate presentation
Mobia Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Mobia Medical initiated with a Buy at BofA with ‘long growth runway’
As previously reported, BofA initiated coverage of Mobia Medical (MOBI) with a Buy rating and $16 price target Mobia has a first mover advantage with its vagus nerve stimulator Vivistim…
Mobia Medical initiated with a Buy at BTIG
BTIG initiated coverage of Mobia Medical (MOBI) with a Buy rating and $19 price target The company develops and commercializes Vivistim, the first and only FDA-approved vagus nerve stimulator platform...
Mobia Medical initiated with a Buy at BofA
BofA initiated coverage of Mobia Medical (MOBI) with a Buy rating and $16 price target
Mobia Medical initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Mobia Medical (MOBI) with an Overweight rating and $15 price target Mobia is commercializing Vivistim Paired Vagus Nerve Stimulation, the first and only FDA-approved the...
Mobia Medical initiated with a Buy at Goldman Sachs
Goldman Sachs analyst David Roman initiated coverage of Mobia Medical (MOBI) with a Buy rating and $31 price target The company offers exposure to a “large and untapped” addressable market…
Mobia Medical indicated to open at $19.50, IPO priced at $15
Mobia Medical (MOBI) priced 10M shares at $15.00. The deal priced at the midpoint of the $14.00-$16.00 range. BofA, JPMorgan, Goldman Sachs, BTIG and Wolfe Research are acting as joint…
Mobia Medical indicated to open at $15, IPO priced at $15
11:44 EDT Mobia Medical (MOBI) indicated to open at $15, IPO priced at $15